Education
About Us
Working with TipRanks
Follow Us
Chimerix (CMRX)
NASDAQ:CMRX
CMRX Analyst Ratings
Hold
1 Buy
3 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
CMRX Stock 12 Month Forecast
Average Price Target
$8.54
▲(0.00%Upside)
| Highest Price Target$8.55 | Average Price Target$8.54 | Lowest Price Target$8.50 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$8.55
Hold
0.12%
Upside
Reiterated
03/21/25
Wedbush
$7→$8.55
Hold
0.12%
Upside
Downgraded
03/05/25
Jefferies
$8.5
Hold
-0.47%
Downside
Downgraded
03/05/25
TD Cowen
$12→$8.55
Buy
0.12%
Upside
Reiterated
03/05/25
Strategic Acquisition and NDA Submission Boost Chimerix's Market Potential6:40 PM CHIMERIX (NASDAQ: CMRX) Buy (1) ESG $8.55 (Prior $12.00) JAZZ TO ACQUIRE CMRX; WE SEE DEAL VALUE AS SOLID AND GOOD TIE IN FOR ONC BIZ THE TD COWEN INSIGHT Jazz announced that it intends to acquire Chimerix for a value of $8.55/share. Given Jazz's interest in the oncology/rare disease space and established commercial presence we believe the deal makes strategic sense, and see the deal value as solid given the overall market opportunity for dordaviprone and Chimerix's early-stage pipeline. We see low FTC risk and expect the deal to close in Q2.
Capital One Financial
$6
Buy
-29.74%
Downside
Reiterated
08/19/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$8.55
Hold
0.12%
Upside
Reiterated
03/21/25
Wedbush
$7→$8.55
Hold
0.12%
Upside
Downgraded
03/05/25
Jefferies
$8.5
Hold
-0.47%
Downside
Downgraded
03/05/25
TD Cowen
$12→$8.55
Buy
0.12%
Upside
Reiterated
03/05/25
Strategic Acquisition and NDA Submission Boost Chimerix's Market Potential6:40 PM CHIMERIX (NASDAQ: CMRX) Buy (1) ESG $8.55 (Prior $12.00) JAZZ TO ACQUIRE CMRX; WE SEE DEAL VALUE AS SOLID AND GOOD TIE IN FOR ONC BIZ THE TD COWEN INSIGHT Jazz announced that it intends to acquire Chimerix for a value of $8.55/share. Given Jazz's interest in the oncology/rare disease space and established commercial presence we believe the deal makes strategic sense, and see the deal value as solid given the overall market opportunity for dordaviprone and Chimerix's early-stage pipeline. We see low FTC risk and expect the deal to close in Q2.
Capital One Financial
$6
Buy
-29.74%
Downside
Reiterated
08/19/24
Best Analysts Covering Chimerix
1 Month
xxx
Success Rate
6/13 ratings generated profit
Average Return
-1.76%
reiterated a xxx
rating 9 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 46.15% of your transactions generating a profit, with an average return of -1.76% per trade.
3 Months
xxx
Success Rate
3/13 ratings generated profit
Average Return
-9.55%
reiterated a xxx
rating 9 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 23.08% of your transactions generating a profit, with an average return of -9.55% per trade.
1 Year
Success Rate
4/13 ratings generated profit
Average Return
+131.76%
reiterated a buy rating 9 months ago
Copying Naureen Quibria's trades and holding each position for 1 Year would result in 30.77% of your transactions generating a profit, with an average return of +131.76% per trade.
2 Years
xxx
Success Rate
4/13 ratings generated profit
Average Return
+181.02%
reiterated a xxx
rating 9 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 30.77% of your transactions generating a profit, with an average return of +181.02% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
CMRX Analyst Recommendation Trends
Rating
Nov 24
Dec 24
Feb 25
Mar 25
Apr 25
Strong Buy
12
17
14
8
3
Buy
1
0
1
2
2
Hold
0
0
0
6
7
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
13
17
15
16
12
Each month's total comprises the sum of three months' worth of ratings.
CMRX Financial Forecast
CMRX Stock Forecast FAQ
What is CMRX’s average 12-month price target, according to analysts?
Based on analyst ratings, Chimerix’s 12-month average price target is 8.54.
What is CMRX’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for CMRX, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is CMRX a Buy, Sell or Hold?
Chimerix has a consensus rating of Hold which is based on 1 buy ratings, 3 hold ratings and 0 sell ratings.
What is Chimerix’s price target?
The average price target for Chimerix is 8.54. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $8.55 ,the lowest forecast is $8.50. The average price target represents 0.00% Increase from the current price of $8.54.
The highest analyst price target is $8.55 ,the lowest forecast is $8.50. The average price target represents 0.00% Increase from the current price of $8.54.
What do analysts say about Chimerix?
Chimerix’s analyst rating consensus is a Hold. This is based on the ratings of 4 Wall Streets Analysts.
How can I buy shares of CMRX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.